Company Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Equities

688192

CNE1000055W8

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 29/04/2024 BST			5-day change	1st Jan Change
45.05 ^CNY	-0.29%		+4.79%	-5.85%

04-29	Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-24	Dizal Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer	CI

Dizal Jiangsu Pharmaceutical Co Ltd is a China-based company mainly engaged in the exploration, research, development and commercialization of innovative biomedicine. The Company focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The Company is still in the R&D stage.

Number of employees: 424

Managers	Title	Age	Since
Xiao Lin Zhang CEO	Chief Executive Officer	60	26/10/17
Wei Wen Dong CHM	Chairman	38	31/05/18
Hong Bin Lu DFI	Director of Finance/CFO	46	30/06/20
Qing Bei Zeng CTO	Chief Tech/Sci/R&D Officer	62	30/11/17
Zhen Fan Yang CTO	Chief Tech/Sci/R&D Officer	56	30/11/17

Members of the board	Title	Age	Since
Simon Lü BRD	Director/Board Member	56	30/09/17
Xue Gong Wang BRD	Director/Board Member	52	06/09/20
Guan Shan Zhu BRD	Director/Board Member	60	07/09/20
Xin Zhang BRD	Director/Board Member	52	07/09/20
Xiao Lin Zhang CEO	Chief Executive Officer	60	26/10/17
Rodolphe Peter Andre Grepinet BRD	Director/Board Member	51	30/09/17
Hong Bin Lu DFI	Director of Finance/CFO	46	30/06/20
Bin Jiang BRD	Director/Board Member	60	07/09/20
Wei Wen Dong CHM	Chairman	38	31/05/18
Yuan Sun BRD	Director/Board Member	36	30/04/19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	415,653,120	76,821,862 ( 18.48 %)	0	18.48 %

Name	Equities	%	Valuation
Hongshan 18.43 %	21,806,801	18.43 %	136 M ¥
LAV Management Co., Ltd. 11.91 %	14,098,432	11.91 %	88 M ¥
Wuxi Xintou Jinshi Venture Capital Management Co. Ltd. 10.08 %	11,930,232	10.08 %	74 M ¥
ELI LILLY AND COMPANY 6.832 %	8,084,411	6.832 %	50 M ¥
Penghua Fund Management Co., Ltd. 4.396 %	5,202,009	4.396 %	32 M ¥
GF Fund Management Co., Ltd. 3.257 %	3,854,123	3.257 %	24 M ¥
Shanghai Sixie Investment Management Co., Ltd. 1.825 %	2,160,000	1.825 %	13 M ¥
Trinity Innovation Fund 1.317 %	1,558,244	1.317 %	10 M ¥
Hwabao WP Fund Management Co., Ltd. 0.4334 %	512,907	0.4334 %	3 M ¥
Bosera Asset Management Co., Ltd. 0.3525 %	417,130	0.3525 %	3 M ¥

Name	Equities	%	Valuation
ASTRAZENECA PLC 37.58 %	108,923,023	37.58 %	678 M ¥
SDIC Innovation Investment Management Co. Ltd. 37.58 %	108,923,023	37.58 %	678 M ¥
Wuxi Dunhe Business Consulting Co. Ltd. 19.82 %	57,451,788	19.82 %	358 M ¥
Dezent Partners Ltd. 1.783 %	5,167,283	1.783 %	32 M ¥

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Building 4 199, 245 Liangjing Road

201203, Shanghai

http://www.dizalpharma.com

address Dizal (Jiangsu) Pharmaceutical Co., Ltd.(688192)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.05 CNY

Average target price

54 CNY

Spread / Average Target

+19.87%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.	-5.85%	2.59B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	103B
REGENERON PHARMACEUTICALS, INC.	+8.96%	101B
ARGENX SE	+4.40%	23.07B
BIONTECH SE	-12.15%	22.23B
GENMAB A/S	-4.36%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.04%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.07B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.35B

Bio Therapeutic Drugs